Califf’s Trial Design Prescription: Less Randomization, More Transparency

FDA’s new deputy commissioner is expected to advocate for innovation in clinical studies; Duke cardiologist has led numerous trials, including pivotal Xarelto study and Vytorin outcomes trial.